
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY AND INSTRUMENT COMBINATION TEMPLATE
A. 510(k) Number:
k160990
B. Purpose for Submission:
New device
C. Measurand:
Uric acid in capillary whole blood
D. Type of Test:
Quantitative, enzymatic, electrode reading
E. Applicant:
Nova Biomedical Corporation
F. Proprietary and Established Names:
Nova Max Uric Acid Monitoring System
G. Regulatory Information:
1. Regulation section:
21 CFR 862.1775, Uric acid test system
2. Classification:
Class I, reserved
3. Product code:
PTC
1

--- Page 2 ---
4. Panel:
Clinical Chemistry (75)
H. Intended Use:
1. Intended use(s):
The Nova Max Uric Acid Monitoring System consists of the Nova Max Uric Acid
Monitor, Nova Max Uric Acid Test Strips and Nova Max Uric Acid Control Solutions.
The Nova Max Uric Acid Monitoring System is intended to be used for the quantitative
measurement of uric acid in fresh capillary whole blood obtained from the fingertip of
gout patients. It is intended for single-patient home use by prescription and should not be
shared. It is intended for self-testing outside the body (in vitro diagnostic use) by people
with gout as an aid to monitor the effectiveness of uric acid control. It is intended for use
by patients undergoing treatment for gout or their caregivers on the order of a treating
healthcare professional. This system should not be used to alter gout treatment by
changing any medication schedule or dosage unless specifically instructed by a
healthcare professional. This system should only be used with single-use, auto-disabling
lancing devices. It should only be used with Nova Max Uric Acid Test Strips and Nova
Max Uric Acid Control Solutions.
2. Indication(s) for use:
See Intended Use.
3. Special conditions for use statement(s):
For prescription use only.
The Nova Max Uric Acid Test Strips give correct results when the following limitations
are observed:
‚Ä¢ Elevated levels of tolazamide, L-dopa, and methyl-dopa may falsely decrease
measured whole blood uric acid.
‚Ä¢ Do not share monitor.
‚Ä¢ Do not reuse! Each Uric Acid Test Strip is for single use only. Use a new Nova Max
Uric Acid Test Strip each time you test.
‚Ä¢ Do not test samples other than fresh capillary whole blood collected from the
fingertip. Do not use serum or plasma.
‚Ä¢ Do not use at altitudes above 15,000 feet (4572 meters) above sea level.
‚Ä¢ Do not use at temperatures outside 59¬∞F to 104¬∞F (15¬∞C to 40¬∞C).
‚Ä¢ Do not use when humidity is higher than 90% or lower than 10% as extremes in
humidity may cause incorrect results.
‚Ä¢ Do not use when hematocrit (% of red blood cells) range is outside the acceptable
hematocrit range of 20% to 65%.
2

--- Page 3 ---
‚Ä¢ Dopamine or ascorbic acid (vitamin C) may cause test results to be incorrect (falsely
low).
‚Ä¢ Ibuprofen, for example Motrin, or drugs that contain ibuprofen, may cause test results
to be falsely high (up to 13% higher).
4. Special instrument requirements:
Nova Max Uric Acid Monitor
I. Device Description:
The Nova Max Uric Acid Monitoring System uses selective mediated enzymatic action
(uricase biosensor) to generate current across the electrodes. The current generated is
proportional to the concentration of uric acid in the capillary whole blood sample. The
device, which is amperometric, measures the uric acid concentration in the whole blood
sample by measuring the amount of current that was generated and flows through the
electrodes on the test strips.
The Nova Max Uric Acid Monitoring System is comprised of Nova Max Uric Acid Test
Strips, a portable handheld Nova Max Uric Acid Monitor, and Nova Max Uric Acid Control
Solutions.
Monitor Power Supply: The monitor uses a single volt (3V) lithium, non-rechargeable
battery. The battery life is approximately 1000 tests.
No-Coding System: The user is not required to enter a test strip lot-specific calibration code.
Uric Acid Control Solutions are aqueous assayed solutions, containing buffered uric acid,
preservatives, FD & C dye, and a viscosity additive. They contain no products of human
origin. There are three levels of controls (level 1, 2, and 3).
When a control solution sample is applied to the Nova Max Uric Acid Test Strip, the monitor
performs a uric acid measurement; the monitor marks the results. The processes of the
monitor operation between measuring the control solution sample and measuring a normal
patient sample are the same.
Safety lancets are provided as an accessory to the Nova Max Uric Acid Monitoring System.
They are commercially available single-use, auto disabling sterilized lancing devices.
J. Substantial Equivalence Information:
1. Predicate device name(s):
URCA Method on the Dimension RxL Max Clinical System
3

--- Page 4 ---
2. Predicate 510(k) number(s):
k043546
3. Comparison with predicate:
Item Nova Max Uric Acid Monitoring Predicate: k043546
System
For the quantitative measurement of uric
Intended Use Same
acid
Enzyme Uricase, Peroxidase Uricase
Uric Acid + 2H O + O + uricase ‚Üí
2 2
Allantoin + H O + CO
2 2
Uric acid + 2H O + O + uricase ‚Üí
2 2
Operating Ferrocyanide + H2O2 + Peroxidase ‚Üí
Allantoin + H O + CO
2 2
Principle Ferricyanide + H2O
(Allantoin absorbs at 293 nm)
Ferricyanide + ‚Üí Ferrocyanide
(on electrode)
Sample type Capillary wholùíÜùíÜe blood from fingertip Serum, plasma
Sample size 1.2 ŒºL 17 ŒºL
Measuring
3 - 18 mg/dL 0 - 20.0 mg/dL
range
Quality
3 levels 2 levels
Control
K. Standard/Guidance Document Referenced (if applicable):
EN 60601-1-2 Electrical Equipment for Measurement, Control and Laboratory use EMC
Requirement
IEC 61010-1:2010 Safety requirements for electrical equipment for measure control and
laboratory use
L. Test Principle:
The Nova Max Uric Acid Monitoring System uses the enzymatic conversion of uric acid by
uricase to allantoin. This reaction quantitatively produces hydrogen peroxide (equation 1).
The hydrogen peroxide then reacts quantitatively with ferrocyanide in the presence of
peroxidase forming ferricyanide (equation 2). The current generated at the electrode by the
conversion of ferricyanide to ferrocyanide is proportional to the uric acid of the sample
(equation 3).
4

[Table 1 on page 4]
Item		Nova Max Uric Acid Monitoring		Predicate: k043546
		System		
Intended Use	For the quantitative measurement of uric
acid			Same
Enzyme	Uricase, Peroxidase			Uricase
Operating
Principle	Uric Acid + 2H O + O + uricase ‚Üí
2 2
Allantoin + H O + CO
2 2
Ferrocyanide + H2O2 + Peroxidase ‚Üí
Ferricyanide + H2O
Ferricyanide + ‚Üí Ferrocyanide
(on electrode)			Uric acid + 2H O + O + uricase ‚Üí
2 2
Allantoin + H O + CO
2 2
(Allantoin absorbs at 293 nm)
Sample type	Capillary wholùíÜùíÜe blood from fingertip			Serum, plasma
Sample size	1.2 ŒºL			17 ŒºL
Measuring
range	3 - 18 mg/dL			0 - 20.0 mg/dL
Quality
Control	3 levels			2 levels

--- Page 5 ---
Uric acid measurement is based on the following equations:
The current generated at the electrode is proportional to the uric acid concentration of the
sample. By measuring the generated current, the concentration of the uric acid in the sample
is determined.
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
A day-to-day precision study was performed by measuring three test strip lots on two
meters, twice a day for twenty days using control solutions. The levels of uric acid
tested were 5, 10.5, and 16 mg/dL. The total imprecision was calculated (which
included test strip lot, meter and day as components of variability):
Total imprecision with control samples
Control
5 mg/dL 10.5 mg/dL 16 mg/dL
Levels
Test Strip
Mean %CV Mean %CV Mean %CV
Lot #
Lot 1 4.88 4.2 10.63 4.4 16.06 3.9
Lot 2 4.88 4.8 10.68 4.2 15.83 3.7
Lot 3 4.93 4.3 10.73 4.0 16.90 3.6
A second precision study was conducted to evaluate within-run precision. Four
different whole blood specimens were prepared with levels of uric acid (4.4, 8.8, 11.8
and 17.1 mg/dL). The specimens were tested 10 times on 5 separate meters (n=50).
The testing was conducted three times using three separate test strip lots. Each test
strip lot was also tested using three different levels of uric acid control solutions (5,
10.5 and 16 mg/dL). Standard deviation was reported for the lowest concentration of
uric acid in the control solution and whole blood samples; % CV for all others.
5

[Table 1 on page 5]
Control
Levels	5 mg/dL		10.5 mg/dL		16 mg/dL	
Test Strip
Lot #	Mean	%CV	Mean	%CV	Mean	%CV
Lot 1	4.88	4.2	10.63	4.4	16.06	3.9
Lot 2	4.88	4.8	10.68	4.2	15.83	3.7
Lot 3	4.93	4.3	10.73	4.0	16.90	3.6

--- Page 6 ---
Within-run precision with venous whole blood samples
Whole Blood Specimens Test Strips Test Strip Lot Test Strip Lot
Lot 1 (n=50) 2 (n=50) 3 (n=50)
Mean 4.5 4.6 4.3
4.4 mg/dL
SD 0.19 0.22 0.19
Mean 8.7 8.6 8.5
8.8 mg/dL
% CV 2.7 2.9 3.5
Mean 11.4 11.3 11.9
11.8 mg/dL
% CV 3.2 3.8 4.2
Mean 16.7 17.0 16.8
17.1 mg/dL
% CV 4.0 3.7 3.4
Within-run precision with control solutions
Control Levels Test Strip Lot Lot 1 Lot 2 Lot 3
Mean (mg/dL) 4.9 4.9 5.0
5 mg/dL (n=50)
S.D. 0.20 0.19 0.18
Mean (mg/dL) 10.6 10.6 10.6
10.5 mg/dL (n=50)
% CV 3.6 3.4 3.7
Mean (mg/dL) 16.0 16.3 16.3
16 mg/dL (n=50)
% CV 3.7 3.4 3.2
b. Linearity/assay reportable range:
Linearity was evaluated using spiked venous whole blood samples with nine different
uric acid levels (2-3, 3-4, 5-6, 7-8, 9-10,11-12,14-15,16-17,19-21 mg/dL). Each
sample was evaluated twice on five separate meters (n=10) and the mean was taken of
the 10 separate measurements. The results demonstrated less than 10% deviation from
the expected value across the range:
Uric Acid Test
Slope Intercept R2
Strip Lot
Lot 1 0.9866 0.2014 0.9943
Lot 2 0.9841 0.2079 0.9964
Lot 3 0.9816 0.1690 0.9957
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Traceability:
Nova Max Uric Acid Monitoring System is traceable to NIST SRM 913B, Uric Acid.
6

[Table 1 on page 6]
Whole Blood Specimens		Test Strips
Lot 1 (n=50)	Test Strip Lot
2 (n=50)	Test Strip Lot
3 (n=50)
4.4 mg/dL	Mean	4.5	4.6	4.3
	SD	0.19	0.22	0.19
8.8 mg/dL	Mean	8.7	8.6	8.5
	% CV	2.7	2.9	3.5
11.8 mg/dL	Mean	11.4	11.3	11.9
	% CV	3.2	3.8	4.2
17.1 mg/dL	Mean	16.7	17.0	16.8
	% CV	4.0	3.7	3.4

[Table 2 on page 6]
Control Levels	Test Strip Lot	Lot 1	Lot 2	Lot 3
5 mg/dL (n=50)	Mean (mg/dL)	4.9	4.9	5.0
	S.D.	0.20	0.19	0.18
10.5 mg/dL (n=50)	Mean (mg/dL)	10.6	10.6	10.6
	% CV	3.6	3.4	3.7
16 mg/dL (n=50)	Mean (mg/dL)	16.0	16.3	16.3
	% CV	3.7	3.4	3.2

[Table 3 on page 6]
Uric Acid Test
Strip Lot	Slope	Intercept	R2
Lot 1	0.9866	0.2014	0.9943
Lot 2	0.9841	0.2079	0.9964
Lot 3	0.9816	0.1690	0.9957

--- Page 7 ---
Stability:
Control solution: The shelf life stability for the Nova Max Uric Acid Control Solution
has been validated for up to 18 months at room temperature, 15 ‚Äì 30 ¬∞C (60 ‚Äì 85 ¬∞F)
on three lots of control solution. The protocols and acceptance criteria were found to
be acceptable.
Test Strip: The shelf life stability for the Nova Max Uric Acid Test Strips has been
validated for up to 18 months at room temperature, 15 ‚Äì 30 ¬∞C (60 ‚Äì 85 ¬∞F) on three
lots of test strips. The protocols and acceptance criteria were found to be acceptable.
Test Strip Open Vial Stability: The open vial stability for the Nova Max Uric Acid
Test Strips has been validated for up to 90 days at room temperature, 15 ‚Äì 30 ¬∞C (60 ‚Äì
85 ¬∞F). The protocols and acceptance criteria were found to be acceptable.
Control solution open vial stability: The open vial stability for the three levels of
Nova Max Uric Acid Control Solution has been validated for up to 90 days at room
temperature, 15 ‚Äì 30 ¬∞C (60 ‚Äì 85 ¬∞F). The protocols and acceptance criteria were
found to be acceptable.
Value Assignment:
The value assignment protocol for the quality control solutions was reviewed and
found to be acceptable.
d. Detection limit:
The limit of blank (LoB) was established by taking 100 measurements of a blank
solution and estimating the LoB non-parametrically as the 95th percentile of the
measurement. This yielded a LoB of 0.26 mg/dL.
Four samples with low concentrations of uric acid (4x LoB or 1.04 mg/dL) were used
to estimate the limit of detection (LoD) and the limit of quantitation (LoQ) of the
device. The LoD was calculated using the following equation: LoB + 1.6494*SD.
The LoQ was the lowest concentration with a CV less than 20%. The results of the
detection limits studies are summarized below:
Analyte LoB LoD LoQ
Uric Acid 0.26 mg/dL 0.54 mg/dL 1.0 mg/dL
Analyte Claimed Measuring Range
Uric Acid 3 ‚Äì 18 mg/dL
7

[Table 1 on page 7]
Analyte	LoB	LoD	LoQ
Uric Acid	0.26 mg/dL	0.54 mg/dL	1.0 mg/dL

[Table 2 on page 7]
Analyte	Claimed Measuring Range
Uric Acid	3 ‚Äì 18 mg/dL

--- Page 8 ---
e. Analytical specificity:
To assess potential interference, venous whole blood samples spiked to three uric acid
concentration ranges (3-9 mg/dL, 9-15 mg/dL and 15-19 mg/dL) were used. Each of
these samples was divided into three pools: control, test pool 1 and test pool 2. The
exogenous and endogenous interfering substances were added to the test pools at
different concentrations. The percent difference between the test samples and the
control sample was calculated. The sponsor defined no significant interference as ‚â§
10% difference between the test samples and the control samples. No interference
was observed with the following compounds at the concentrations listed:
Substance Concentrations Tested
Acetaminophen 5 and 20 mg/dL
Ascorbic acid 0.6 and 3 mg/dL
Bilirubin 10 and 20 mg/dL
Creatinine 1.2 and 6 mg/dL
Dopamine 0.6 and 1 mg/dL
Ephedrine 0.3 and 0.9 mg/dL
Folic acid 10 and 20 mg/dL
Glucose 300 and 900 mg/dL
Heparin 19,500 and 39,000 IU/dL
Hydroxyurea 15 and 30 mg/dL
Salicyclic acid 10 and 20 mg/dL
Tetracycline hydrochloride 10 and 30 mg/dL
Tolbutamide 15 and 45 mg/dL
Triglycerides 750 and 1250 mg/dL
Vitamin B7 10 and 20 mg/dL
Vitamin B12 10 and 20 mg/dL
Warfarin 10 and 20 mg/dL
The following compounds and concentrations were found to interfere with the test:
‚Ä¢ L-dopa above 0.4 mg/dL produced falsely low values
‚Ä¢ Methyl-dopa above 1.8 mg/dL produced falsely low values
‚Ä¢ Tolazamide above 14 mg/dL produced falsely low values
‚Ä¢ Ibuprofen above 16 mg/dL produced falsely high values
The following information is presented in the package insert to describe interferences
observed:
‚Ä¢ Individuals taking dopamine or ascorbic acid may experience falsely low
results
‚Ä¢ Elevated levels of tolazamide, L-dopa, and methyl-dopa may falsely decrease
measured whole blood uric acid.
8

[Table 1 on page 8]
Substance	Concentrations Tested
Acetaminophen	5 and 20 mg/dL
Ascorbic acid	0.6 and 3 mg/dL
Bilirubin	10 and 20 mg/dL
Creatinine	1.2 and 6 mg/dL
Dopamine	0.6 and 1 mg/dL
Ephedrine	0.3 and 0.9 mg/dL
Folic acid	10 and 20 mg/dL
Glucose	300 and 900 mg/dL
Heparin	19,500 and 39,000 IU/dL
Hydroxyurea	15 and 30 mg/dL
Salicyclic acid	10 and 20 mg/dL
Tetracycline hydrochloride	10 and 30 mg/dL
Tolbutamide	15 and 45 mg/dL
Triglycerides	750 and 1250 mg/dL
Vitamin B7	10 and 20 mg/dL
Vitamin B12	10 and 20 mg/dL
Warfarin	10 and 20 mg/dL

--- Page 9 ---
‚Ä¢ If you are taking Ibuprofen, for example Motrin, or drugs that contain
ibuprofen, your test results may be falsely high (up to 13% higher).
f. Assay cut-off:
Not applicable.
2. Comparison studies:
a. Method comparison with predicate device:
Described in the clinical studies below in 3c.
b. Matrix comparison:
Not applicable.
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
User Accuracy Study:
A clinical study using laypersons na√Øve to this type of test was conducted using a total
of 143 subjects who collected and tested their own fingerstick capillary whole blood
samples in singlicate. Lay-users performed the testing without assistance from the
healthcare professionals. Lithium heparin plasma samples were then obtained from
the users for comparison to the predicate. The results of the testing by the lay-users
using the proposed device were compared to the results of the plasma samples using
the predicate device. Three different strip lots were used in the testing and each lot of
strips was subject to standard shipping and handling conditions prior to the testing.
The range of the results in the study was from 3.2 ‚Äì 17.5 mg/dL uric acid. The results
using Deming Regression of the study are summarized in the table below.
9

--- Page 10 ---
Nova Max-Capillary Fingertip vs.
Siemens Dimension RxL Max Venous
N 143
Slope 0.957
R2 0.98
Intercept (mg/dL) 0.137
Human Factors Study:
A human factors study using 120 laypeople previously diagnosed with gout was
conducted in the U.S. to evaluate the Nova Max Uric Acid Monitoring System. The
goal of the study was to determine the subjects‚Äô ability to use the device. The lay-
users were provided the labeling; they used the device and filled out a questionnaire.
From the data recorded, 99.2% (119/120) of the subjects were able to successfully
perform a capillary fingerstick whole blood measurement and 97.5% (117/120) of the
subjects were able to successfully perform a control solution test. The response to the
questionnaire indicated that the participants were able to understand the labeling,
understand the test result and operate the Nova Max Uric Acid Monitoring System.
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
Nova performed a reference range study to determine reference uric acid levels in
capillary whole blood obtained from the fingertip of adult subjects (139 males and 150
females) who were not taking any medications known to affect uric acid levels in the
blood, and who did not present with any conditions known to elevate or reduce levels of
uric acid in the blood.
The central 95% reference interval for uric acid in capillary whole blood obtained from a
fingerstick was 3.6 ‚Äì 7.7 mg/dL in healthy males and 2.6 ‚Äì 6.2 mg/dL for healthy
females. These upper and lower reference limits show agreement with published ranges
of serum uric acid levels in adult populations.
N. Instrument Name:
Nova Max Uric Acid Monitor
10

[Table 1 on page 10]
	Nova Max-Capillary Fingertip vs.
Siemens Dimension RxL Max Venous
N	143
Slope	0.957
R2	0.98
Intercept (mg/dL)	0.137

--- Page 11 ---
O. System Descriptions:
1. Modes of Operation:
Does the applicant‚Äôs device contain the ability to transmit data to a computer, webserver,
or mobile device?
Yes ________ or No ___X____
Does the applicant‚Äôs device transmit data to a computer, webserver, or mobile device
using wireless transmission?
Yes ________ or No __X____
2. Software:
FDA has reviewed applicant‚Äôs Hazard Analysis and software development processes for
this line of product types:
Yes ____X___ or No ________
3. Specimen Identification:
There is no sample identification function with this device. Samples are applied directly
to the test strip as they are collected.
4. Specimen Sampling and Handling:
The uric acid test is intended to be used with capillary whole blood from the finger. The
whole blood sample is applied directly to the test strip.
5. Calibration:
There is no calibration required for the meter by the user. The meter is automatically
coded.
6. Quality Control:
Uric Acid Control Solutions are aqueous assayed solutions, containing buffered uric acid,
preservatives, FD & C dye, and a viscosity additive. They contain no products of human
origin. There are three levels of controls (level 1, 2, and 3).
When a control solution sample is applied to the Nova Max Uric Acid Test Strip, the
monitor performs a uric acid measurement; the monitor marks the results as a quality
11

--- Page 12 ---
control sample. The processes of the monitor operation between measuring the control
solution sample and normal patient uric acid sample are same.
P. Other Supportive Instrument Performance Characteristics Data Not Covered In The
‚ÄúPerformance Characteristics‚Äù Section above:
1. Sample Volume Study
The nominal fill indicated by the labeling of the device is 1.2 Œºl of capillary whole blood.
A study was performed to determine the minimum fill volume of the test strip. Five
different meters were tested with three whole blood samples spiked to different uric acid
concentrations (5.1, 10.2, and 16.8 mg/dL). Different volumes of whole blood were
added to the test strips to determine the minimum volume to trigger the device to take a
reading. 0.8, 0.9, 1.0, 1.1, 1.2, 1.3 Œºl were tested with three different lots of test strips.
100% (90/90) of the test strips triggered a reading at sample volumes ‚â• 1.2 Œºl. 89/90 of
the samples triggered readings at 1.1 Œºl. No test result was released for the remaining
1/90 or for the other volumes tested less than 1.1 Œºl. These results support the claimed
sample volume of 1.2 Œºl.
2. Altitude Study
The effect of altitude was simulated by changing the amount of dissolved oxygen in
whole blood with a tonometer to simulate the oxygen concentration in blood at three
different altitudes. Two different meters with three venous whole blood samples spiked
with uric acid (5.1, 10.2, and 16.8 mg/dL) were used in the study. The result were
compared to results obtained using the predicate device. The study demonstrated that the
reported uric acid results in whole blood are constant across different pO2 levels and that
altitude up 15,000 feet (4572 meters) above sea level did not impact the reported uric acid
results.
3. Hematocrit Study:
Three different test strip lots were analyzed at five different hematocrit levels (20, 35, 45,
55, and 65%) using five venous whole blood samples spiked with uric acid (3.4, 7.3,
10.8, 14.3, and 18.1 mg/dL) on five different meters. The result were compared to results
obtained using the predicate device. The performance of the three lots of test strips
demonstrates that the hematocrit levels tested did not affect the performance of the uric
acid system.
4. Test System Operating Conditions ‚Äì humidity and temperature:
Three different test strip lots were analyzed at five different temperature and humidity
combinations (5 C/10% humidity, 5C/90%, 25 C/50%, 40 C/10% and 40 C/90%
humidity) on five different meters using three whole blood samples spiked with uric acid
(6.3, 9.9, and 16.8 mg/dL). The result were compared to results obtained using the
predicate device. The uric acid control solutions were also evaluated at the five different
12

--- Page 13 ---
temperature and humidity concentrations on five different meters. The performance of the
device was not significantly affected by the variation in temperature or humidity for
either the whole blood samples or the control solutions.
5. Accelerated Bench Testing Using Clorox Germicidal Disposable Wipes:
Accelerated cleaning protocols of the monitors were done on four separate devices to
evaluate the deterioration of the device due to regular cleaning as indicated in the product
labeling. Each monitor was cleaned and disinfected 10,950 times to simulate 10 cycles
per day on each monitor for a period of 3 years. None of the four monitors tested showed
any deterioration of the housing material, the display screen, the power button and all
four devices passed the internal test procedures for functionality of all monitor
components including the electronics, display, beeper, test strip port reader and buttons.
6. Disinfection Efficacy/Infection Control Study:
The device is intended for single-patient use. Disinfection efficacy studies were
performed on the materials comprising the meter by an outside commercial testing
laboratory demonstrating complete inactivation of hepatitis B virus (HBV) with the
Clorox Healthcare Germicidal Wipes, EPA# 67619-12. The meter passed the evaluation
of virus elimination protocol acceptance criteria with the Clorox Healthcare Bleach
Germicidal Wipes.
7. Pre and Post Cleaning and Disinfection Precision and Accuracy Study:
To evaluate the precision of the four monitors used in the accelerated cleaning protocol
above, each monitor took 25 measurements of 5 blood specimens with different uric acid
concentrations before and after the cleaning/disinfection cycles. Accuracy was evaluated
by measuring five whole blood samples with each of the four meters for five different
uric acid concentrations before and after the 10,950 cleaning cycles and comparing the
results to the predicate as well as the meters before the cleaning. The 10,950 cleaning and
disinfection cycles on the Nova Max did not impact the analytical performance of the
monitors.
8. Customer Support Center assistance, call 1-800-681-7390 Monday - Saturday, 9:00 AM -
5:30 PM ET.
Q. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
R. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
13